Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DGOQ25
|
|||
| Drug Name |
CBL-514
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Subcutaneous fat disorder [ICD-11: EF02] | Phase 2 | [1] | |
| Company |
Caliway Biopharmaceuticals New Taipei City, Taiwan
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04897412) A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 2). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.